The history of Alzheimer’s research has been filled with setback after setback – in fact nearly every clinical trial has failed – but it is also one marked by perseverance and renewed hope. Advancements in medical imaging have increased our understanding of how the disease strikes, and efforts are underway to develop diagnostics to treat the disease before its onset. 

With a growing aging population, how will the disease burden the country’s health care system? The Atlantic will gather leading experts and key stakeholders for a national conversation on what it will take to disrupt Alzheimer’s disease.

Where

Chez
247 East Ontario Street
Chicago, IL 60611

When

Wednesday, September 12, 2018
8:00 AM - 10:30 AM CDT

Speakers

• Peter Anastasiou, executive vice president, head of North America, Lundbeck
• Samantha Budd Haeberlein, vice president, Alzheimer’s late stage clinical development, Biogen
• Daisy Duarte, caregiver, clinical trial participant, and advocate for LatinosAgainstAlzheimer’s
• Sarita Gupta, co-executive director, Jobs with Justice; co-director, Caring Across Generations
• Harry Johns, president and CEO, Alzheimer’s Association
• Elli Kaplan, co-founder and CEO, Neurotrack
• William Klein, professor, department of neurobiology, Northwestern University
• Juliet Holt Klinger, senior director, dementia care, Brookdale Senior Living
• Jill Lesser, president, WomenAgainstAlzheimer’s
• Stephanie Monroe, executive director, AfricanAmericansAgainstAlzheimer's
• Jay Newton-Small, co-founder, MemoryWell
• George Vradenburg, chairman and co-founder, UsAgainstAlzheimer's
• Johan Luthman, vice president and head of clinical development, Global Neurology Business Group, Eisai
• Rep. Bill Foster (D-IL)